FI3654989T3 - Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon - Google Patents

Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon Download PDF

Info

Publication number
FI3654989T3
FI3654989T3 FIEP18739593.4T FI18739593T FI3654989T3 FI 3654989 T3 FI3654989 T3 FI 3654989T3 FI 18739593 T FI18739593 T FI 18739593T FI 3654989 T3 FI3654989 T3 FI 3654989T3
Authority
FI
Finland
Prior art keywords
cladribine
composition
use according
unit dosage
treatment
Prior art date
Application number
FIEP18739593.4T
Other languages
English (en)
Finnish (fi)
Inventor
Konrad Rejdak
Original Assignee
Chord Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chord Therapeutics Sa filed Critical Chord Therapeutics Sa
Application granted granted Critical
Publication of FI3654989T3 publication Critical patent/FI3654989T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
FIEP18739593.4T 2017-07-21 2018-06-28 Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon FI3654989T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE

Publications (1)

Publication Number Publication Date
FI3654989T3 true FI3654989T3 (fi) 2024-03-21

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18739593.4T FI3654989T3 (fi) 2017-07-21 2018-06-28 Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon

Country Status (16)

Country Link
US (2) US12171775B2 (enExample)
EP (2) EP3654989B1 (enExample)
JP (1) JP7186214B2 (enExample)
CA (1) CA3095893A1 (enExample)
DK (1) DK3654989T3 (enExample)
ES (1) ES2974423T3 (enExample)
FI (1) FI3654989T3 (enExample)
GB (1) GB2564717A (enExample)
HR (1) HRP20240282T1 (enExample)
HU (1) HUE066238T2 (enExample)
LT (1) LT3654989T (enExample)
PL (1) PL3654989T3 (enExample)
PT (1) PT3654989T (enExample)
RS (1) RS65246B1 (enExample)
SI (1) SI3654989T1 (enExample)
WO (1) WO2019016505A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
AU2024399689A1 (en) 2023-12-14 2026-07-30 Ares Trading S.A. Cladribine regimen for treating myasthenia gravis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
AU6234000A (en) * 1999-07-22 2001-02-13 Supergen, Inc. Methods for treating autoimmune diseases
AU2003286836A1 (en) * 2002-10-31 2004-06-07 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
EP1567945A2 (en) * 2002-11-22 2005-08-31 Transclick, Inc. System and method for speech translation using remote devices
ES2584183T3 (es) 2003-03-28 2016-09-26 Ares Trading S.A. Formulaciones de cladribina para suministro mejorado oral y transmucosa
PL2805723T3 (pl) * 2004-12-22 2018-04-30 Merck Serono Sa Schemat dawkowania kladrybiny dla leczenia stwardnienia rozsianego
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.

Also Published As

Publication number Publication date
HRP20240282T1 (hr) 2024-05-10
EP3654989B1 (en) 2024-01-03
GB201711800D0 (en) 2017-09-06
EP4292663A3 (en) 2024-03-20
US20200163986A1 (en) 2020-05-28
PT3654989T (pt) 2024-02-28
US20250302858A1 (en) 2025-10-02
US12171775B2 (en) 2024-12-24
WO2019016505A1 (en) 2019-01-24
GB2564717A (en) 2019-01-23
DK3654989T3 (da) 2024-02-26
EP3654989A1 (en) 2020-05-27
PL3654989T3 (pl) 2024-05-20
LT3654989T (lt) 2024-03-25
SI3654989T1 (sl) 2024-06-28
ES2974423T3 (es) 2024-06-27
HUE066238T2 (hu) 2024-07-28
RS65246B1 (sr) 2024-03-29
JP2020527156A (ja) 2020-09-03
EP4292663A2 (en) 2023-12-20
CA3095893A1 (en) 2019-01-24
JP7186214B2 (ja) 2022-12-08

Similar Documents

Publication Publication Date Title
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
KR101900520B1 (ko) 복합 조성물
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2018138596A5 (enExample)
RU2013127420A (ru) Способы уменьшения психогенного или компульсивного переедания
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
JP2016505050A5 (enExample)
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
EP4389218A3 (en) Composition for treating joint disease and kit containing same
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
HRP20240282T1 (hr) Upotreba kladribina za liječenje autoimune neuromuskularne bolesti
JP2020527156A5 (enExample)
IL300144A (en) Benzazepines are combined for the treatment of Tourette syndrome
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
RU2014113967A (ru) Комбинированная терапия рассеянного склероза интерфероном и андрографолидами
RU2013124994A (ru) КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
CN103989685A (zh) 一种复方拉莫三嗪皮下埋植缓释胶棒的制备方法
CN102772472A (zh) 一种治疗寻常疣的酊剂药物
CN103054823A (zh) 一种以溴地斯的明为活性成分的固体制剂
CN109806245A (zh) 一种以雪松醇为原料制备镇痛和治疗关节炎功能的药物
CN103385907A (zh) 鼻炎缓释通
Korneva et al. Ciprofloxacin: instruction as a source of information and the degree of its reliability
CN104107204A (zh) 一种治疗脑萎缩及面神经瘫痪的药物组合物